SS-31 (Elamipretide) (10mg)

Research Overview

A mitochondria-targeted tetrapeptide that concentrates >1000-fold in the inner mitochondrial membrane, selectively binding cardiolipin. By stabilizing cardiolipin-cytochrome c interactions, SS-31 optimizes electron transport chain efficiency and reduces ROS production at the source.

Origin: Developed by Dr. Hazel Szeto at Weill Cornell Medicine

Mechanism of Action

• Cardiolipin binding in inner mitochondrial membrane

• Electron transport chain optimization

• ROS reduction at source (not scavenging)

• Cytochrome c stabilization

• Mitochondrial membrane potential preservation

Primary Research Areas

• Mitochondrial dysfunction

• Heart failure

• Renal ischemia

• Barth syndrome

• Age-related mitochondrial decline

Key Published Findings

• Concentrated >1000-fold in mitochondria within minutes

• Improved cardiac function in heart failure models (Dai et al., JACC, 2013)

• Advanced to Phase 3 clinical trials for Barth syndrome

Research Protocol

Commonly studied routes: Subcutaneous, Intravenous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.

Storage

-20°C lyophilized

Important Notice

SS-31 (Elamipretide) (10mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.